Insmed Inc. to Webcast 2006 Second Quarter Financial Results Conference Call, Tuesday, August 8, 2006 at 4:30 p.m. (ET)
07 Août 2006 - 10:16PM
Business Wire
Insmed (NASDAQ:INSM) announced today that it will release its 2006
second quarter financial results tomorrow, Tuesday, August 8, 2006
after market close. The Company will host a conference call
tomorrow, August 8 at 4:30 p.m. Eastern Time to discuss the
financial results and provide a business update. Interested
investors can listen to the call over the internet from Insmed's
investor relations website at www.insmed.com or by dialling
800-361-0912 (domestic) or 913-981-5559 (international). A
telephonic replay of the call will be available for one week at
888-203-1112 (domestic) or 719-457-0820 (international), passcode:
1703416. A web replay of the call will be available through the
corporate website beginning at 6:00 p.m. About Insmed Incorporated
Insmed is a biopharmaceutical company focused on the development
and commercialization of drug candidates for the treatment of
metabolic diseases and endocrine disorders with unmet medical
needs. For more information, please visit www.insmed.com. The
company's leading product, IPLEX was approved as an orphan drug by
the United States Food and Drug Administration in December 2005 for
the treatment of growth failure in children with severe primary
IGF-I deficiency (Primary IGFD) or with growth hormone (GH) gene
deletion who have developed neutralizing antibodies to GH. About
IPLEX IPLEX, a complex of recombinant human IGF-I and its binding
protein IGFBP-3 (rhIGF-I/rhIGFBP-3), is the only once-daily IGF-I
replacement therapy. It is also the only FDA-approved therapy that
provides both IGF-I and IGFBP-3 to treat children with severe
primary IGFD. The drug, to be launched during the second quarter of
2006, is also being investigated for various other indications with
unmet medical needs, including extreme insulin resistance, myotonic
muscular dystrophy and HIV Associated Adipose Redistribution
Syndrome (HARS). About the Condition Severe primary IGFD is a
genetic or acquired condition in which patients do not generate
sufficient quantities of insulin-like growth factor-I (IGF-I) due
to defect in the growth hormone (GH) receptor/IGF-I pathway. Gene
mutations leading to growth failure due to IGF-I deficiency have
been identified in the growth hormone receptor, in the GH receptor
signalling pathway, and in the IGF-I gene itself. Patients with
severe primary IGFD present with marked short stature and a poor
prognosis for adult stature.
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024